GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Catheter Precision Inc (AMEX:VTAK) » Definitions » Net-Net Working Capital

Catheter Precision (Catheter Precision) Net-Net Working Capital : $-1.05 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Catheter Precision Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Catheter Precision's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-1.05.

The industry rank for Catheter Precision's Net-Net Working Capital or its related term are showing as below:

VTAK's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.48
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Catheter Precision Net-Net Working Capital Historical Data

The historical data trend for Catheter Precision's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catheter Precision Net-Net Working Capital Chart

Catheter Precision Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial 1,962.25 189.30 58.36 3.83 -0.83

Catheter Precision Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.79 -0.76 -0.83 -1.05

Competitive Comparison of Catheter Precision's Net-Net Working Capital

For the Medical Devices subindustry, Catheter Precision's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catheter Precision's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Catheter Precision's Price-to-Net-Net-Working-Capital falls into.



Catheter Precision Net-Net Working Capital Calculation

Catheter Precision's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.565+0.75 * 0.137+0.5 * 0.044-9.544
-0-0)/7.02663
=-0.83

Catheter Precision's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.491+0.75 * 0.073+0.5 * 0.063-9.497
-0-0)/7.5734
=-1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Catheter Precision  (AMEX:VTAK) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Catheter Precision Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Catheter Precision's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Catheter Precision (Catheter Precision) Business Description

Traded in Other Exchanges
Address
1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708
Catheter Precision Inc Formerly Ra Medical Systems Inc is a commercial-stage medical device company whose business comprises of the design, manufacture and sale of new medical technologies in the field of cardiac electrophysiology, or EP. Its product, View into Ventricular Onset System or VIVO System which is a non invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. . It operates business as one segment which includes all activities related to the marketing, sales and development of medical technologies in the field of cardiac EP.
Executives
David A Jenkins director, officer: Executive Chairman of Board P.O. BOX 682838, PARK CITY UT 84068
Steven K Passey officer: Chief Financial Officer 3216 SOUTH HIGHLAND DRIVE, SUITE 200, SALT LAKE CITY UT 84117
James Joseph Caruso director 28 FIRST AVE, SEASIDE PARK NJ 08752
Brian Conn officer: Chief Financial Officer MICROISLET, INC., 6370 NANCY RIDGE DRIVE, SUITE 112, SAN DIEGO CA 92121
Andrew C. Jackson officer: CFO & Secretary 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Jonathan Will Mcguire director, officer: Chief Executive Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Susanne Meline director P.O. BOX 515381, #86506, LOS ANGELES CA 90051
Martin J Colombatto director
Richard Jr Mejia director 2200 FARADAY AVENUE, SUITE 100, CARLSBAD CA 92008
William R Enquist director 11810 WILLS ROAD, ALPHARETTA GA 30009
Joan Stafslien director CAREFUSION CORPORATION, 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Daniel Horwood officer: General Counsel C/O RA MEDICAL SYTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Jeffrey J Kraws officer: Co-President 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Dean Irwin director, 10 percent owner, officer: See Remarks C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Martin Burstein 10 percent owner C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011